Computational Studies on the Substrate Interactions of Influenza A Virus PB2 Subunit

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wang, Ya Jun ^a   Wang, Jing Fang ^a,b   Ping, Jie ^a   Yu, Yao ^b,d   Wang, Ying ^a   Lian, Peng ^a   Li, Xuan ^b,d   Li, Yi Xue ^b,c   Hao, Pei ^b,e  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d INSTITUTE OF PLANT PHYSIOLOGY AND ECOLOGY   (China)

^e INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

7 METHYLGUANOSINE TRIPHOSPHATE; ARGININE; CAP BINDING PROTEIN; GLUTAMIC ACID; GLUTAMINE; GUANINE; GUANOSINE TRIPHOSPHATE DERIVATIVE; HISTIDINE; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS POLYMERASE BASIC PROTEIN 2; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CALCULATION; COMPLEX FORMATION; COMPUTER SIMULATION; CRYSTAL STRUCTURE; DRUG DESIGN; ENERGY; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; FREE ENERGY; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA VIRUS A; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; VIRTUAL REALITY;

ANTIVIRAL AGENTS; CELL NUCLEUS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HYDROGEN BONDING; INFLUENZA A VIRUS; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR CONFORMATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; RNA CAP ANALOGS; RNA CAPS; RNA REPLICASE; RNA, VIRAL; SUBSTRATE SPECIFICITY; THERMODYNAMICS; VIRAL PROTEINS;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84866007816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044079     Document Type: Article

References (58)

1. Eccles R, (2005) Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 5: 718-725.
2. Lee RV, (2007) Transmission of influenza in human beings. Lancet Infect Dis 7: 759-760.
3. Tang JW, Li Y, (2007) Transmission of influenza A in human beings. Lancet Infect Dis 7: 758.
4. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y, (2008) Human infection with highly pathogenic H5N1 influenza virus. Lancet 371: 1464-1475.
5. Olsen B, Munster VJ, Wallensten A, Waldenström J, Osterhaus AD, et al. (2006) Global patterns of influenza A virus in wild birds. Science 312: 384-388.
6. Lamb RA, Choppin PW, (1993) The gene structure and replication of influenza virus. Annu Rev Biochem 52: 467-506.
7. Bouiver NM, Palese P, (2008) The biology of influenza viruses. Vaccine 26: D49-D53.
8. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of vrial genome evolution. Nature 437: 1162-1166.
9. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246.
10. Barroso L, Treanor J, Gubareva L, Hayden FG, (2005) Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Their 10: 901-910.
11. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, et al. (1999) Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 282: 31-35.
12. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH, (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4: 3021-3024.
13. Beigel J, Bray M, (2008) Current and future antiviral therapy of severe seasonal and avian influenza. Antivir Res 78: 91-102.
14. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI, (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
15. Leung TWC, Tai ALS, Cheng PKC, Kong MSY, Lim W, (2009) Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 46: 298-299.
16. Wang NX, Zheng JJ, (2009) Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci 18: 707-715.
17. Pielak RM, Schnell JR, Chou JJ, (2009) Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA 106: 7379-7384.
18. Wang JF, Wei DQ, Chou KC, (2009) Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus. Biochem Biophys Res Commun 388: 413-417.
19. Pielak RM, Chou JJ, (2010) Flu channel drug resistance: a tale of two sites. Protein Cell 1: 246-258.
20. Sharma M, Yi M, Dong H, Qin H, Peterson E, et al. (2010) Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer. Science 330: 509-512.
21. Wang JF, Chou KC, (2010) Insights from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel 23: 663-666.
22. Coloma R, Valpuesta JM, Arranz R, Carrascosa JL, Ortin J, et al. (2009) The structure of a biologically active influenza virus ribonucleoprotein complex. PLoS Pathogens 5: e1000491.
23. Murti KG, Webster RG, Jones IM, (1988) Localization of RNA polymerases of influenza viral ribonucleoproteins by immunogold labeling. Virology 164: 562-566.
24. Plotch SJ, Bouloy M, Ulmanen I, Krug RM, (1981) A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 23: 847-858.
25. Li ML, Rao P, Krug RM, (2001) The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. EMBO J 20: 2078-2086.
26. Guilligay D, Terendeau F, Resa IP, Coloma R, Crepin T, et al. (2008) The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15: 500-506.
27. Wang Y, Wei DQ, Wang JF, (2010) Molecular dynamics studies on T1 lipase: insight into a double-flap mechanism. J Chem Inf Model 50: 875-878.
28. Wang JF, Chou KC, (2011) Insights from modeling the 3D structure of New Delhi metallo-ß-lactamse and its binding interactions with antibiotic drugs. PLoS One 6: e18414.
29. Lian P, Wei DQ, Wang JF, Chou KC, (2011) An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes. PLoS One 6: e18587.
30. Georgescu RE, Alexov EG, Gunner MR, (2002) Combining conformational flexibility and continuum electrostatics for calculating pK(a)s in proteins. Biophys J 83: 1731-1748.
31. Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation program. J Comput Chem 26: 1668-1688.
32. Ponder JW, Case DA, (2003) Force field for protein simulations. Adv Protein Chem 66: 27-85.
33. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH, et al. (2000) Cheatham, T.E. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
34. Chen HF, Luo R, (2007) Binding induced folding in p53-MDM2 complex. J Am Chem Soc 129: 2930-2937.
35. Wang J, Tan C, Chen HF, Luo R, (2008) All-atom computer simulations of amyloid fibrils disaggregation. Biophys J 95: 5037-5047.
36. Qin F, Chen Y, Li YX, Chen HF, (2009) Induced fit for mRNA/TIS11d complex. J Chem Phys 131: 115103.
37. Qin F, Jiang Y, Chen Y, Wu M, Yan G, et al. (2011) Conformational selection or induced fit for Brinker and DNA recognition. Phys Chem Chem Phys 13: 1407-1412.
38. Wang JF, Chou KC, (2012) Insights into the mutation-induced HHH syndrome from modling human mitochondrial ornithine transporter-1. PLoS One 7: e31048.
39. Wang JF, Hao P, Li YX, Dai JL, Li X, (2012) Exploration of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations. J Mol Model 18: 2717-2725.
40. Chen HF, (2009) Molecular dynamics simulation of phosphorylated KID post-translational modification. PLoS One 4: e6516.
41. Li J, Wei DQ, Wang JF, Li YX, (2011) A negative cooerativity mechanism of human CYP2E1 inferred from molecular dynamics simulations and free energy calculations. J Chem Inf Model 51: 3217-3225.
42. Chen Y, Li Z, Chen HF, (2010) Computational study of CCR5 antagonist with support vector machines and three dimensional quantitative structure activity relationship methods. Chem Biol Drug Des 75: 295-309.
43. Willett P, (1998) Chemical similarity searching. J Chem Inf Comput Sci 38: 983-996.
44. Iwai Y, Takahashi H, Hatakeyama D, Motoshima K, Ishikawa M, et al. (2010) Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. Bioorg Med Chem 18: 5379-5390.
45. Gao Z, Li H, Zhang H, Liu X, Kang L, et al. (2008) PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 9: 104.
46. Gu H, Chen HF, Wei DQ, Wang JF, (2010) Molecular dynamics simulations exploring drug resistance in HIV-1 protease. Chinese Sci Bull 55: 2677-2683.
47. Zeng QK, Du HL, Wang JF, Wei DQ, Wang XN, et al. (2009) Reversal of coenzyme specificity and improvement of catalytic efficiency of Pichia stipitis xylose reductase by rational site-directed mutagenesis. Biotechnol Lett 31: 1025-1029.
48. Macrotrigiano J, Gingras AC, Sonenberg N, Burley SK, (1997) Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89: 951-961.
49. Calero G, Wilson KF, Ly T, Rios-Steiner JL, Clardy JC, et al. (2002) Structural basis of m7GpppG binding to the nuclear cap-binding protein complex. Nat Struct Biol 9: 912-917.
50. Hodel AE, Gershon PD, Quiocho FA, (1998) Structural basis for sequence-nonspecific recognition of 5′-capped mRNA by a cap-modifying enzyme. Mol Cell 1: 443-447.
51. Ishida T, Doi M, Inoue M, (1988) A selective recognition mode of a nucleic acid based by an aromatic amino acid: L-phenylalnine-7-methylguanosine 5′-monophosphate stacking interaction. Nucleic Acids Res 16: 6175-6190.
52. Darzynkiewicz E, Lonnberg H, (1989) Base stacking of simple mRNA cap analogues. Association of 7,9-dimethylguanine, 7-methylguanosine and 7-methylguanosine 5′-monophosphate with indole and purine derivatives in aqueous solution. Biophys Chem 33: 289-293.
53. Ueda H, Iyo H, Doi M, Inoue M, Ishida T, (1991) Cooperative stacking and hydrogen bond pairing interactions of fragment peptide in cap binding protein with mRNA cap structure. Biochim Biophys Acta 1075: 181-186.
54. Stolarski R, Sitek A, Stepinski J, Jankowska M, Oksman P, et al. (1996) 1H-NMR studies on association of mRNA cap-analogues with tryptophan-containing peptides. Biochim Biophys Acta 1293: 97-105.
55. Niedzwieck A, Marotrigiano J, Stepinski J, Jankowska-Anyszka M, Wyslouch-Cieszynska A, et al. (2002) Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5′ cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol 319: 615-635.
56. Hu G, Gershon PD, Hodel AE, Quiocho FA, (1999) mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains. Proc Natl Acad Sci USA 96: 7149-7154.
57. Hooker L, Sully R, Handa B, Ono N, Koyana H, et al. (2003) Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E. Biochemistry 42: 6234-6240.
58. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 46: 2-36.